BMY — Bristol-Myers Squibb Co Share News
0.000.00%
Last trade - 00:00- $110.27bn
- $144.28bn
- $48.19bn
Janux Therapeutics up after nominating cancer therapy in Bristol Myers deal
Brief: Bristol Myers Squibb Presents Positive Results From Phase 3 Scout-Hcm Trial Demonstrating Efficacy And Safety Of Camzyos (Mavacamten) In Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy (Ohcm)
Brief: Bristol-Myers Squibb Says Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics To Cobenfy
Brief: FDA Approves Nivolumab With Chemotherapy For Previously Untreated Hodgkin Lymphoma
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma (updated)
US FDA approves Bristol Myers Squibb's cancer drug for Hodgkin's lymphoma
Brief: Bristol Myers Squibb To Report Results For First Quarter 2026 On April 30, 2026
US FDA approves J&J's oral psoriasis pill (updated)
US FDA approves J&J's oral psoriasis pill
FTC monitoring how drug companies react to patent cliff, official says
U.S. RESEARCH ROUNDUP- Biogen, Eli Lilly, Johnson & Johnson
Health Rounds: Eliquis proves safer than Xarelto for patients with deep blood clots
Bristol's cancer drug meets main goal in late-stage trial (updated)
Brief: Bristol Myers Reports Positive Phase 3 Results For Oral Mezigdomide In Relapsed Myeloma
Bristol's cancer treatment meets main goal in late-stage trial
Brief: Bristol Myers Squibb Announces Dividend
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP
Brief: Bristol Myers Squibb Announces Positive Top-Line Results From Registrational Phase 2 Study Of Luspatercept
U.S. RESEARCH ROUNDUP-Akamai Technologies, Albemarle, Nordson